SCHEMBL10243020

SCHEMBL10243020

CCCCNC(=O)c1ccnc2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.60
TSHR P16473 1/20 0.60
FAP Q12884 2/20 0.56
NSD2 O96028 1/20 0.54
HPGD P15428 3/20 0.54
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 3/20 0.53
GAA P10253 2/20 0.53
GLA P06280 1/20 0.53
POLB P06746 1/20 0.53
APOBEC3A P31941 1/20 0.53
ESR2 Q92731 1/20 0.53
CTDSP1 Q9GZU7 1/20 0.53
APOBEC3G Q9HC16 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
DRD4 P21917 2/20 0.52
DRD2 P14416 1/20 0.52
HDAC1 Q13547 2/20 0.51
HDAC2 Q92769 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244776 0.90 NSD2 (0.64) HTTTSHRFAPNSD2HPGD
SCHEMBL12903049 0.85 NSD2 (0.59) FAPNSD2HDAC1HDAC2HDAC3
SCHEMBL31047590 0.85 NSD2 (0.61) HTTTSHRFAPNSD2HPGD
SCHEMBL31047570 0.85 NSD2 (0.61) HTTTSHRFAPNSD2HPGD
SCHEMBL10245901 0.83 HTT (0.56) HTTTSHRHPGDKDM4EALDH1A1
SCHEMBL9001093 0.83 KDM4E (0.61) HTTNSD2HPGDKDM4EALDH1A1
SCHEMBL11025228 0.81 HTT (0.57) HTTTSHRHPGDKDM4EALDH1A1
SCHEMBL2402489 0.81 NSD2 (0.65) FAPNSD2KDM4EGAAPOLB
Methyl Alcohol SCHEMBL11081976 0.80 HTT (0.56) HTTTSHRHPGDKDM4EALDH1A1
SCHEMBL5016070 0.80 NSD2 (0.53) FAPNSD2DRD4DRD2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 HTT 868/4885TSHR 1567/4885FAP 3307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.